Substance Use Disorder Prevalence among Female State Prison Inmates

Proctor, Steven L.

doi:10.3109/00952990.2012.668596

Cited by 46 publications

(39 citation statements)

References 30 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, our participants were exclusively from New York City and their experiences may not be representative of the experiences of inmates in other geographic locations. Second, most of our study sample was male, while substance use disorders are prevalent among female inmates who constitute the fastest growing inmate demographic in the United States (Proctor, 2012). Third, more of our participants were currently receiving buprenorphine treatment than methadone, leading to possible selection bias.…”

Section: Discussionmentioning

confidence: 99%

“I Kicked the Hard Way. I Got Incarcerated.” Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments

Maradiaga

Nahvi

Cunningham

et al. 2016

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

Incarceration is a common experience for individuals with opioid use disorder, including those receiving medication assisted treatments (MAT), such as buprenorphine or methadone. In the United States, MAT is rarely available during incarceration. We were interested in whether challenges with methadone maintenance treatment during incarceration affected subsequent attitudes toward MAT following release. We conducted semi-structured interviews with 21 formerly incarcerated individuals with opioid use disorder in community substance abuse treatment settings. Interviews were audio recorded, transcribed, and analyzed using a grounded theory approach. Themes that emerged upon iterative readings of transcripts were discussed by the research team. The three main themes relating to methadone were: 1) rapid dose reduction during incarceration; 2) discontinuity of methadone during incarceration; and 3) post incarceration aversion to methadone. Participants who received methadone maintenance treatment prior to incarceration reported severe and prolonged withdrawal symptoms from rapid dose reductions or disruption of their methadone treatment during incarceration. The severe withdrawal during incarceration contributed to a subsequent aversion to methadone and adversely affected future decisions regarding reengagement in MAT. Though MAT is the most efficacious treatment for opioid use disorder, current penal policy, which typically requires cessation of MAT during incarceration, may dissuade individuals with opioid use disorder from considering and engaging in MAT after release from incarceration.

show abstract

Section: Discussionmentioning

confidence: 99%

“I Kicked the Hard Way. I Got Incarcerated.” Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments

Maradiaga

Nahvi

Cunningham

et al. 2016

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

show abstract

“…A 2006 Bureau of Justice Statistics report shows that half of inmates have at least one mental health problem(Glaze & James, 2006). Recent research has documented the unusually high rates of incarcerated women’s SMI(Binswanger et al, 2010; DeHart, Lynch, Belknap, Dass-Brailsford, & Green, 2013; Lynch et al, in press; Steadman, Osher, Clark Robbins, Case, & Samuels, 2009) and SUD(Abram, Teplin, & McClelland, 2003; Daniel, Robins, Reid, & Wilfley, 1988; Proctor, 2012). Complicating these high rates is the high comorbidity of SMI with SUD and trauma histories (Abram, et al, 2003; Butler, India, Allnutt, & Mamoon, 2011; Lynch, Fritch, & Heath, 2012).…”

mentioning

confidence: 99%

Risk Profile and Treatment Needs of Women in Jail with Co-Occurring Serious Mental Illness and Substance Use Disorders

et al. 2014

View full text Add to dashboard Cite

Recent research has documented the unusually high rates of incarcerated women’s serious mental illness (SMI) and substance use disorders (SUD). Complicating these high rates is the high comorbidity of SMI with SUD and trauma histories. Yet, incarcerated women have significantly less access to treatment and health services while incarcerated than men. We used data from a multi-site, multi-method project funded by the Bureau of Justice Assistance (2011–2012) to determine the risk profile of women in jail (n=491) with a current co-occurring SMI (i.e., major depressive disorder, bipolar disorder, schizophrenia spectrum disorder)and SUD (i.e., abuse, dependence). The study spanned multiple geographic regions, and structured diagnostic interviews were used to understand better the women that comprised this vulnerable population. One-in-five of the women had a current co-occurring disorder (CCOD). The findings revealed that significantly more women with a CCOD had been exposed to violence and were exposed to drugs at a younger age. Further, about one-third of women with a CCOD had received no treatment from a health care professional in the past year, demonstrating a substantial unmet need. We conclude that investing in mental and behavioral health care in jails is critical to the health and safety of women as well as the communities to which they return.

show abstract

“…Another study based on routine clinical assessment of 801 imprisoned women on admission into prison demonstrated that 70% were dependent on at least one substance and 7.9% met criteria for substance abuse. 21 These studies indicate that the prevalence of psychiatric illness in prisoners is significantly elevated, with rates higher than those found in the community for most mental disorders. [24][25][26][27] It is believed, however, that the mental health problems found cannot be attributed to the stress of imprisonment alone.…”

Section: Introductionmentioning

confidence: 97%

“…Early traumatic events and childhood sexual and physical abuse are highly prevalent in forensic samples. 19 Furthermore, studies have shown a high degree of comorbid psychopathologies, namely substance dependence 20,21 and PTSD. 22 Moreover, research has shown that over 80% of imprisoned women have had at least one DSM-IV-TR psychiatric diagnosis in their lifetime and that 70% have met criteria for a disorder in the last 6 months.…”

Section: Introductionmentioning

confidence: 99%

Serum concentrations of brain-derived neurotrophic factor and mental disorders in imprisoned women

Dotta-Panichi

Bins

Tramontina

et al. 2015

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: Mental disorders and early trauma are highly prevalent in female inmates. Brain-derived neurotrophic factor (BDNF) plays an important role in learning, memory processes, and mood regulation. The aim of this study was to evaluate the relationship between serum BDNF levels and mental disorders among imprisoned women as compared with age-and education-matched controls. Methods: A consecutively recruited sample of 18 female prisoners with mental disorders was assessed for sociodemographic, criminal, and clinical variables using standardized instruments, the Mini International Neuropsychiatric Interview Plus (MINI Plus), and serum BDNF levels. Results: High rates of childhood sexual abuse and posttraumatic stress disorder (PTSD) were found in the group of forensic patients. Serum BDNF levels in the forensic group did not differ from those of healthy controls, and were significantly higher when compared with those of women with mental disorders hospitalized in a general hospital. Conclusion: Elevated serum BDNF levels were found in imprisoned women. The results of this study may suggest neurobiological mechanisms similar to those seen in previous clinical and preclinical studies showing the involvement of BDNF in the pathophysiology of PTSD.

show abstract

Substance Use Disorder Prevalence among Female State Prison Inmates

Cited by 46 publications

References 30 publications

“I Kicked the Hard Way. I Got Incarcerated.” Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments

“I Kicked the Hard Way. I Got Incarcerated.” Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments

Risk Profile and Treatment Needs of Women in Jail with Co-Occurring Serious Mental Illness and Substance Use Disorders

Serum concentrations of brain-derived neurotrophic factor and mental disorders in imprisoned women

Contact Info

Product

Resources

About